7-[(1R,5S,6S)-6-氨基-1-甲基-3-氮杂双环[3.2.0]庚烷-3-基]-1-环丙基-6-氟-4-氧代-1,8-萘啶-3-羧酸

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 7-[(1R,5S,6S)-6-氨基-1-甲基-3-氮杂双环[3.2.0]庚烷-3-基]-1-环丙基-6-氟-4-氧代-1,8-萘啶-3-羧酸
• 英文名称: ecenofloxacin
• 英文别名: 7-([1α,5α,6β]-6-amino-1-methyl-3-azabicyclo[3.2.0]heptane-3-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphtyridine-3-carboxylic acid；7-([1α,5α,6β]-6-amino-1-methyl-3-azabicyclo[3.2.0]heptane-3-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid；1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-([1α,5α, 6β]6-amino-1-methyl-3-azabicyclo[3.2.0]heptan-3-yl)-1,8-naphtyridine-3-carboxylic acid；7-[(1R,5S,6S)-6-azaniumyl-1-methyl-3-azabicyclo[3.2.0]heptan-3-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylate
• 化学式: C₁₉H₂₁FN₄O₃
• 分子量: 372.399
• InChiKey: WNVIWAUAXKEKKF-PJFSTRORSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  99.8
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  [1α,5α,6β]-6-amino-1-methyl-3-azabicyclo[3.2.0]heptane 、 环丙基萘啶羧酸 在 环丙基萘啶羧酸 作用下， 以77的产率得到7-[(1R,5S,6S)-6-氨基-1-甲基-3-氮杂双环[3.2.0]庚烷-3-基]-1-环丙基-6-氟-4-氧代-1,8-萘啶-3-羧酸
  参考文献：
  名称：

  Pyridone carboxylic acid compounds and their uses for treating

  摘要：

  提供了由以下公式表示的吡啶酮羧酸化合物或生理水解酯：##STR1##其中，R.sub.1是较低的烷基，卤代较低的烷基，较低的烯基，环烷基或取代或未取代的苯基；R.sub.2是氢原子，或较低的烷基或氨基；A是氮原子或C-X基团，其中X是氢或卤素原子，或烷氧基；Z是具有以下公式的基团：##STR2##其中n为1或2；R.sub.3和R.sub.4各代表氢原子或较低的烷基，但如果n为2，则R.sub.3和R.sub.4中的一个为氢原子；R.sub.5和R.sub.6各代表氢原子，或羟基，较低的烷氧基或氨基，该氨基未经取代或由较低的烷基取代，但其中一个为氢原子；R.sub.7是氢原子或较低的烷基。本发明的化合物表现出强大和广谱的抗菌活性。

  公开号：

  US05527910A1

文献信息

• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• [EN] METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES<br/>[FR] PROCÉDÉS DE SYNTHÈSE DE CARBONATES DE N-HYDROXYSUCCINIMIDYLE
  申请人：XENOPORT INC

  公开号：WO2010017498A1

  公开（公告）日：2010-02-11

  The present disclosure relates to methods of synthesizing N-hydroxysuccinimidyl-carbonate intermediates from the corresponding sulfones useful in the preparation of 1-(acyloxy)-alkyl carbamate prodrugs.

  本公开涉及一种从相应砜合成N-羟基琥珀酰亚胺-碳酸酯中间体的方法，该中间体在制备1-(酰氧基)-烷基氨甲酸酯前药中有用。
• METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS
  申请人：XENOPORT, INC.

  公开号：US20140243544A1

  公开（公告）日：2014-08-28

  Methods of preparing carbamate prodrugs of amine-containing drugs are provided. Carbonates useful in the synthesis of the carbamate prodrugs are also provided.

  提供了制备胺类药物的氨基甲酸酯前药的方法。还提供了在合成氨基甲酸酯前药中有用的碳酸盐。
• Glucuronidated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014734A1

  公开（公告）日：2007-01-18

  This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol and/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also provides methods of treating and/or preventing vascular diseases, by administering at least one glucuronidated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one glucuronidated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  这项发明提供了葡萄糖醛酸化的尼布ivolol代谢物以及用于治疗心血管疾病的葡萄糖醛酸化的尼布ivolol代谢物的制药组合物。此外，该发明还提供了包含尼布ivolol和/或至少一种尼布ivolol的葡萄糖醛酸化代谢物和/或至少一种其他活性化合物的药用可接受载体的组合物。该发明还提供了通过向受影响血管疾病的靶位点投与至少一种能释放治疗有效量一氧化氮的尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防血管疾病的方法。此外，该发明旨在通过投与至少一种尼布ivolol的葡萄糖醛酸化代谢物来治疗和/或预防偏头痛。该发明还可与代谢综合征紊乱的单一治疗或联合治疗一起使用。
• Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
  申请人：Gallop A. Mark

  公开号：US20050222431A1

  公开（公告）日：2005-10-06

  Methods for synthesis of 1 -(acyloxy)-alkyl carbamates, particularly, the synthesis of 1 -(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1 -(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1 -(acyloxy)-alkyl carbamates are also described.

  本文介绍了合成1-(酰氧基)-烷基氨基甲酸酯的方法，特别是合成含有一级或二级胺类药物的1-(酰氧基)-烷基氨基甲酸酯前药的方法。同时还介绍了合成1-(酰氧基)-烷基N-羟基琥珀酰亚胺碳酸酯的方法，这些化合物是合成1-(酰氧基)-烷基氨基甲酸酯的有用中间体。